Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer ; day:16 ; month:5 ; year:2024 ; pages:1-11
Breast cancer research and treatment ; (16.5.2024), 1-11
- Urheber
-
Woo, Ji Won
Han, Eun Kyung
Suh, Koung Jin
Kim, Se Hyun
Kim, Jee Hyun
Park, So Yeon
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-024-07359-x
- URN
-
urn:nbn:de:101:1-2407252102001.034477473109
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Woo, Ji Won
- Han, Eun Kyung
- Suh, Koung Jin
- Kim, Se Hyun
- Kim, Jee Hyun
- Park, So Yeon
- SpringerLink (Online service)
Ähnliche Objekte (12)
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer